Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
US9834594B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 6, 2017 |
| Grant date | Dec 5, 2017 |
| Priority date | — |
| Expiry date | Jan 6, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2469/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.